명인제약

317450KOSPI의약품 제조업

64.1 / 100

Reference Date: 2026-04-13

Financial Score30.5 / 40

News Sentiment15.6 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and ROE significantly exceeds the industry average is also solid. Slightly down 4.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Myungin Pharmaceutical specializes in developing and producing CNS-focused specialty pharmaceuticals, including treatments for stroke, Parkinson's disease, and depression, securing the top position in the domestic market according to IQVIA 2025 Q4 data. Leveraging its full-process production capabilities from raw material synthesis to finished products, the company expands partnerships with global pharmaceutical firms and maintains a strong market presence in OTC products as well.

Number of Employees

532people

Average Salary

78.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

8.53Industry Average 14.806.5Point

Lower than industry avg (good)

PBR

1.05Industry Average 1.042.5Point

Higher than industry avg (caution)

ROE

12.28Industry Average 4.427.0Point

2.8x industry avg (excellent)

Debt Ratio

0.14Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 6.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

3.5 / 4

Detailed News Sentiment

4 totalPositive 1Neutral 1Negative 0Average Sentiment Score 75

Positive
명인제약, 공동대표 체제 전환…R&D·영업 투트랙 강화
명인제약이 이관순, 차봉권 공동대표 체제로 전환하여 R&D와 영업 부문을 강화하고 신약 중심 사업 구조 전환 및 중장기 성장 전략을 추진합니다.
Neutral
'IB 강자' KB증권, IPO 실적 공백…강진두 대표 역량 시험대
KB증권의 IPO 실적 공백과 강진두 대표의 역량 시험대에 대한 뉴스이며, 명인제약과 직접적인 관련이 없습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 57,300Won52-week high 121,90052-week low 52,500

1-month return2.0Point

1m -4.50% (slight drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-04-06
Neutral기업가치제고계획(자율공시)2026-03-27
Neutral정기주주총회결과2026-03-26
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
Neutral대표이사(대표집행임원)변경(안내공시)2026-03-26